News

Lincoln Pharmaceuticals Ltd. submitted a certificate to the National Stock Exchange of India Limited and BSE Limited, confirming receipt of a confirmation certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, regarding dematerialization of securities for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Lincoln Pharmaceuticals Ltd. will close its trading window from October 1, 2026, until 48 hours after the announcement of its financial results for the quarter ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s Code of Practices & Procedures for Fair Disclosure.

Lincoln Pharmaceuticals Limited informed the National Stock Exchange of India Limited and the BSE Limited that its 32nd Annual General Meeting is scheduled for Wednesday, September 30, 2026, and the record date for determining entitlement to a final dividend of Rs 1.80 per equity share, representing 18% of the face value of Rs 10, is Friday, September 11, 2026, with a book closure from Saturday, September 12, 2026, to Wednesday, September 30, 2026.

Lincoln Pharmaceuticals Limited informed the National Stock Exchange of India Limited and the BSE Limited that its 32nd Annual General Meeting is scheduled to be held on Wednesday, September 30, 2026, and the book closure will be from Saturday, September 12, 2026, to Wednesday, September 30, 2026, to determine the eligibility of shareholders for a final dividend of Rs 1.80 per equity share of face value Rs 10 each, representing 18% for the financial year April 01, 2025, to March 31, 2026.

Lincoln Pharmaceuticals Ltd share price slipped 1.06% to Rs 591.1 after the company`s net profit saw a strong growth of 211.52% to Rs 36.23 crore, while revenue from operations eased by 5.34% to Rs 177.28 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.25%. It has inched up 0.97% over last one week and heading higher by 11.17% in last one month while the market capitalization of Lincoln Pharmaceuticals Ltd has slipped by 3.02% and 8.36% in the same period respectively. Profit before tax (PBT) of Lincoln Pharmaceuticals Ltd stood at Rs 47.55 crore in Q2 FY26, expanding by 34.36% year-on-year, and surging by 184.73% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 62.88% YoY and nosediving by 89.09% sequentially. Total expenses slightly declined by 7.45% to Rs 153.73 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 58.58 crore, plunging by 20.55% YoY, while employee benefits expense was at Rs 33.31 crore, inching up 2.62% YoY. For the TTM ended FY26, revenue from operations inched higher 7.35% to Rs 623.23 crore, while net profit dropped 11.74% to Rs 82.35 crore, compared to previous TTM. EBITDA jumped by 6677% to Rs 79.01 crore, and PBT fell 10.68% to Rs 109.19 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 93.02 crore in FY26, as against Rs 63.22 crore in FY25. Lincoln Pharmaceuticals Ltd rallied 8.29% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.